Showing results (11-20 of 302) with videos related to
Sort By:
Pageof 31
Medical Oncology (Northwood, London, England)|July 31, 2012
Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regressionFausto Petrelli, Sandro BarniRadiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 18, 2011
Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trialsFausto Petrelli, Sandro BarniBreast Cancer Research and Treatment|November 2, 2013
Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancerFausto Petrelli, Sandro BarniCurrent Opinion in Obstetrics & Gynecology|February 24, 2006
Locally advanced breast cancerSandro Barni, Mario MandalàMedical Oncology (Northwood, London, England)|March 3, 2010
Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debateFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|July 2, 2013
Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trialsFausto Petrelli, Sandro BarniMedical Oncology (Northwood, London, England)|November 26, 2013
Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trialsFausto Petrelli, Sandro BarniTranslational Lung Cancer Research|March 26, 2015
Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trialsFausto Petrelli, Sandro BarniBreast Cancer Research and Treatment|November 24, 2021
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx studySandro Barni, Francesco Cognetti, Fausto PetrelliExpert Review of Anticancer Therapy|November 5, 2015
Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agentsAndrea Coinu, Fausto Petrelli, Sandro BarniPageof 31